Abstract: Optical or light diffusers (or, simply, “diffusers”) designed and manufactured to include numerous facets arranged in cells or sets in which the planar faces or outward-facing surfaces have orientations and transmission angles (as may be defined by direction cosines of normal) to redirect received light to a region or portion of a predefined light distribution. A method of designing or defining the facets of the diffuser is also provides as are methods of manufacturing the diffusers and apparatus or products that include the new diffusers (such as microdisplays and lighting components). The diffusers are optically designed to produce a user-specified distribution of light. The diffusers can be engineered through the configuration of the facets on its front or outer surface (light transmission surface) to produce nearly any type of light distribution or shape, and the diffuser design facilitates their manufacture using extrusion processes as well as other fabrication techniques.

Abstract: Methods, systems, computer-readable media, devices, and apparatuses for synchronized mode transitions are presented. A first device configured to be worn at an ear includes a processor configured to, in a first contextual mode, receive a first mode change request from a second device to transition at a first time to a second contextual mode. The first mode change request is based on detection of a trigger condition. The processor is further configured to, at the first time, transition from the first contextual mode to the second contextual mode based on the first mode change request.

Abstract: A system includes: an electrical apparatus that includes: a housing that defines an interior space; an active portion in the interior space; and insulation configured to electrically insulate at least part of the active portion. The system also includes a monitoring apparatus configured to: receive measured data from the electrical apparatus; determine a load forecast for the electrical apparatus based on the measured data; determine whether a pre-determined time interval has elapsed; and after the pre-determined time interval has elapsed: estimate an actual amount of life lost for the insulation during the pre-determined time interval that elapsed based on the measured data; estimate a predicted amount of life lost for the insulation during one or more future time intervals based on the load forecast; and estimate a remaining service life for the electrical apparatus based on the actual amount of life lost and the predicted amount of life lost.

Abstract: An electrical apparatus includes: a housing that defines an interior space; an active portion in the interior space, the active portion including one or more electrically conductive coils; a fluid in the interior; and a control system configured to: determine a difference between a measured temperature of the fluid and an estimated temperature of the fluid; and determine whether a performance condition exists based on the difference.

Abstract: Disclosed herein are cocrystals of cannabidiol and a coformer containing 5-6 membered rings comprised of carbon and nitrogen atoms, wherein the 5-6 membered rings can be unsaturated or saturated and the rings contain 1 to 2 nitrogen atoms.

Abstract: This invention provides stable, highly crystalline forms of Complement Factor D inhibitor Compound 3 for therapeutic applications.

Abstract: The present invention describes a pharmaceutical preparation in which a reactive chlorine-oxygen compound is provided in the form of a medicament inhalable into the lungs.

Abstract: A system includes a monitoring module configured to: receive a first indication related to a three-phase input of a three-phase AC electrical asset; receive a second indication related to a three-phase output of the three-phase AC electrical asset; determine performance metrics for the three-phase AC electrical asset based on the first indication and the second indication; determine error metrics by comparing each determined performance metrics to a pre-determined estimated performance metric; compare each of the error metrics to one of a plurality of pre-determined thresholds, the thresholds being determined when the three-phase AC electrical asset is in a healthy condition; and determine whether a developing fault condition exists in the three-phase AC electrical asset based on the comparison.

Abstract: The present invention describes a pharmaceutical preparation for use in the treatment of systemic inflammatory response syndrome (SIRS).

Abstract: Locating systems and methods for wireless seat belt monitoring in vehicles with removable or reconfigurable seats are provided herein. An example remote transceiver can be centrally located on a seat that is configured to be rearranged within a vehicle. The remote transceiver can include a processor and memory for storing instructions that include a unique code identifying the remote transceiver. The processor executes the instructions to receive low power signals from transmitters within an interior of the vehicle, determine received signal strength values of the low power signals. The received signal strength values are used by the vehicle receiver to determine a location of the remote transceiver within the vehicle.

Abstract: Disclosed herein are cocrystals of cannabidiol and a coformer containing 5-6 membered rings comprised of carbon and nitrogen atoms, wherein the 5-6 membered rings can be unsaturated or saturated and the rings contain 1 to 2 nitrogen atoms. Cocrystals of cannabidiol and a coformer selected from L-proline, D-proline, tetramethylpyrazine, and 4,4?-dipyridyl are also disclosed herein.

Abstract: The invention relates to a pharmaceutically active substance comprising at least one peptide portion having the amino acid sequences m-v-v-y-f-r (first peptide portion), characterised in that the pharmaceutically active substance comprises at least additional one amino acid and/or peptide portion at the N-terminal end and/or at the C-terminal end of the first peptide portion (second peptide portion and/or third peptide portion) being directly bound to the peptide portion having the amino acid sequences m-v-v-y-f-r (first peptide portion). The invention further relates to a pharmaceutical composition and a drug for the treatment of cancer.

Abstract: The disclosure is directed to crystalline forms of the compound of Formula I, pharmaceutically acceptable salts of the compound of Formula I, and crystalline forms thereof. Pharmaceutical compositions comprising said crystalline forms and salts, as well as methods of their use and preparation, are also described.

Abstract: Described herein are solid state 17?-ethynylandrost-5-ene-3?,7?,17?-triol including amorphous and crystalline forms and specific polymorphic forms thereof, and use of solid state 17?-ethynylandrost-5-ene-3?,7?,17?-triol in treating numerous diseases and disorders, including hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions, and neurodegenerative conditions in subjects or human patients.

Abstract: This invention provides stable, highly crystalline forms of Complement Factor D inhibitor Compound 3 for therapeutic applications.

Abstract: Disclosed herein are cocrystals of cannabidiol and a coformer containing 5-6 membered rings comprised of carbon and nitrogen atoms, wherein the 5-6 membered rings can be unsaturated or saturated and the rings contain 1 to 2 nitrogen atoms.

Abstract: Locating systems and methods for wireless seat belt monitoring in vehicles with removable or reconfigurable seats are provided herein. An example device includes a first transceiver associated with a seat belt buckle, the first transceiver having a processor and memory for storing instructions that include a first unique code identifying the first transceiver and a first orientation value of the seat belt buckle to a vehicle receiver, the first orientation value indicating a location of the seat belt buckle on a seat, the processor executes the instructions to transmit the first unique code and the first orientation value to a vehicle receiver.

Abstract: Locating systems and methods for wireless seat belt monitoring in vehicles with removable or reconfigurable seats are provided herein. An example device includes a first transceiver associated with a seat belt buckle, the first transceiver having a processor and memory for storing instructions that include a first unique code identifying the first transceiver and a first orientation value of the seat belt buckle to a vehicle receiver, the first orientation value indicating a location of the seat belt buckle on a seat, the processor executes the instructions to transmit the first unique code and the first orientation value to a vehicle receiver.

Abstract: Locating systems and methods for wireless seat belt monitoring in vehicles with removable or reconfigurable seats are provided herein. An example remote transceiver can be centrally located on a seat that is configured to be rearranged within a vehicle. The remote transceiver can include a processor and memory for storing instructions that include a unique code identifying the remote transceiver. The processor executes the instructions to receive low power signals from transmitters within an interior of the vehicle, determine received signal strength values of the low power signals. The received signal strength values are used by the vehicle receiver to determine a location of the remote transceiver within the vehicle.

Abstract: Described herein are solid state 17?-ethynylandrost-5-ene-3?,7?,17?-triol including amorphous and crystalline forms and specific polymorphic forms thereof, and use of solid state 17?-ethynylandrost-5-ene-3?,7?,17?-triol in treating numerous diseases and disorders, including hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions, and neurodegenerative conditions in subjects or human patients.